Read the latest news from around the worlds on Biotechnology, Clinical Trial Results, FDA Calendar, FDA Events, FDA Device Approvals and more
Source: www.rttnews.com
Novartis announced new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed-dose combination asthma treatment containing indacaterol acetate, glycopyrronium bromide, and mometasone furoate, delivered with the dose-confirming Breezhaler inhalation device. In two phase II clinical studies, IND/GLY/MF was superior to the comparators, salmeterol/fluticasone propionate (a standard-of-care treatment) and placebo, separately by demonstrating improvement in lung function in patients with asthma.
